Media

November, 2019, an article in MIRROR REVIEW, 4HF BIOTEC: A Novel Approach For Cancer Treatment.

                https://www.mirrorreview.com/4hf-biotec-novel-approach-cancer-treatment/

-----------------------------------

 

October 26 - 30, 2019, 4HF Biotec will be presenting at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston

Posters :

 

# C075 - “The use of 4HF Cancer Data Miner platform for an In Silico pharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib”

Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Session Date: Tuesday, October 29 -12.30 -16 PM

 

# C060 – “Broad spectrum activity of the MDM2 inhibitor MI-773 in hematologic and solid cancer cell lines in-vitro and determination of predictive biomarkers”

Session Title: Therapeutic Agents-- Other
Session Date: Tuesday, October 29 -12.30 -16 PM

 

-----------------------------------

 

October 8 -11, 2019, 4HF Biotec will be presenting in collaboration with Bionavigen at 10th Annual World ADC, San Diego

Poster entitled :

#01 - "4HF Cancer Data Miner platform for an accelerated

In Silico ADC target discovery and evaluation"

-----------------------------------
 

July 2019, StartupCity selected 4HF Biotec in the top 15 most promising Biotec startups in Europe

Links:

https://biotech-europe.startupcity.com/vendors/top-biotech-startups-in-europe-2019.html

https://biotech-europe.startupcity.com/vendor/4hf-biotec-bringing-forth-novel-anticancer-drugs-cid-290-mid-34.html

-----------------------------------

18th July 20194HF Biotec today announces that it has entered into a collaboration with Bionavigen in the field of target and drug discovery.

-----------------------------------

Mar 2019, 4HF will participate at the AACR ANNUAL MEETING 2019, Mar 29-Apr 3, Atlanta, United States.

 

Visit our posters: Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers. Abstract nr 2196.

 

and,

 

Broad spectrum activity of the BET inhibitor GSK 1324726A in hematologic and solid cancer cell lines in-vitro and determination of associated predictive biomarkers. Abstract nr 3074.

                                                 ------------------------------------

Nov 2018, 4HF Biotec will participate at the 30th EORTC-NCI-AACR SYMPOSIUM : Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics that will take place 13-16 Nov, Dublin, Ireland. We will be very pleased to meet you there!

 

Visit our poster: #PB-039, Title : Broad spectrum activity of Sabutoclax in haematological and solid cancer cell lines is associated with defined biomarkers. Section "Molecular Targeted Agents" on 13 November 2018

------------------------------------

Apr 2018, 4HF Biotec will participate at the AACR Annual Meeting 2018 April 14-18,  Chicago, Illinois, USA

                                                 -----------------------------------

Mar 2018, 4HF Biotec will participate at the World ADC 2018, 26–28 March, Berlin, Germany

------------------------------------

Feb 2018, 4HF Biotec will participate at the 39th EORTC-PAMM Winter Meeting; 7-10Feb, Roma, Italy

-----------------------------------

Oct 2017, 4HF Biotec will participate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics that will take place October 26-30, 2017,  Philadelphia, Pennsylvania. 

 

We will take this opportunity to present our poster #B167, entitled : ”KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 Inhibitor”  October 29, 2017, 12:30 - 4:00 PM, Hall E

We are very pleased to meet you at this event, do not hesitate to visit our poster or to contact us for a discussion.